Skip to main content

Table 2 Baseline characteristics

From: A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma

 

Placebo (n = 166)

Grass AIT (n = 163)

Female, no. (%)

88 (53%)

88 (54%)

Race, no. (%)

  

  White

134 (81%)

134 (82%)

  Black

21 (13%)

21 (13%)

  Hispanic/Latino

6 (4%)

4 (2%)

  Non-smoker

121 (73%)

128 (79%)

Previous smoker, no. (%)

24 (14%)

26 (16%)

Smoker, no. (%)

21 (13%)

9 (6%)

Age, y

  

  Mean (SD)

35.9 (11.7)

35.9 (11.7)

  Range

18-62

18-65

Subjects with asthma, no. (%)

43 (26%)

46 (28%)

Sensitive to non-grass allergens per skin prick, no. (%)

  

  White oak

74 (45%)

75 (46%)

  White birch

84 (51%)

87 (53%)

  Animal hair/dander (cat)

77 (46%)

79 (48%)

  House dust mite

86 (52%)

93 (57%)

Mean duration of pre-treatment (weeks), [range]

16.2 [5.9, 23.9]

16.3 [6.4, 23.7]

  1. AIT Allergy immunotherapy tablet, DSS Daily symptom score, SD Standard deviation.